95 results
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
)
Consolidated income statement
Three months ended
31 March
(thousands of €, except per share data)
Total net revenues
Cost of sales
Research … and development expenses
Sales and marketing expenses
General and administrative expenses
Other operating income
Operating loss
Fair value adjustments and net
6-K
EX-99.7
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
July 2019, the Company announced that it entered into a 10-year global research and development collaboration with Gilead Sciences, Inc. (“Gilead … , License and Collaboration Agreement with Gilead Sciences
On 14 July 2019, the Company and Gilead Sciences entered into a 10-year global research
6-K
EX-99.5
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
by categories of activity
Research & Development
Royalties
Sales of trading products
Allocation by geographical market
US - United States
FR - France
DE … in research and development projects. Research and development expenses are, as of fiscal year 2010, recorded on the assets only to the extent
6-K
EX-99.9
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
that it entered into a 10-year global research and development collaboration with Gilead Sciences, Inc. Within the framework of such collaboration … and support its research and development programs or to enable the Company to react to new research and development opportunities in a quick
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
-therapy research and development through the acquisitions of CellPoint (in the Netherlands) and Abound Bio (in the U.S). The transactions provide us … research and development, and we are applying our small molecule approach to the discovery and
development of potentially best-in-class precision medicines
6-K
EX-99.1
pgzc pfzr
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
trxsnnp78zjd96 522c7
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
S-8
EX-4.1
qhd9q sxo31
4 Dec 23
Registration of securities for employees
5:16pm
6-K
EX-99.1
u3ktsk
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
y9e9j0v73qo3oy0mtqfl
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.2
6w8v3yma14rvnv9bl
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
cxjtif
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
phvhyagmwvq3x
31 Mar 23
Current report (foreign)
6:05am
S-8
EX-4.1
akl1u w7vedz
12 Dec 22
Registration of securities for employees
4:08pm
6-K
EX-99.1
1edek smn
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
zw08wpo9fqcjysya
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
vst15x
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-3.1
sgrdnsy3fwydh73tx9
11 May 22
Current report (foreign)
4:05pm